Reduced-Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation with Once-Daily Intravenous Busulfan for Relapsed/Refractory Lymphoma: A Phase II Study
- 19 June 2026
- journal article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (11) , 1415.e1-1415.e5
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- The salvage role of allogeneic hematopoietic stem-cell transplantation in relapsed/refractory diffuse large B cell lymphomaScientific Reports, 2023
- Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?Blood, 2012
- High Busulfan Exposure Is Associated with Worse Outcomes in a Daily i.v. Busulfan and Fludarabine Allogeneic Transplant RegimenTransplantation and Cellular Therapy, 2008
- Allogeneic haematopoietic stem‐cell transplantation for relapsed and refractory aggressive histology non‐Hodgkin lymphoma*British Journal of Haematology, 2005
- Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: Study of pharmacokinetics and early clinical outcomesTransplantation and Cellular Therapy, 2002